Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients … – Yahoo Finance

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

Information on solriamfetol featured in two oral plenary classes

NEW YORK, Might 29, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical firm creating and delivering novel therapies for the administration of central nervous system (CNS) issues, at this time introduced 5 shows, together with two featured oral plenary shows, on solriamfetol at SLEEP 2024, the thirty eighth annual assembly of the American Academy of Sleep Medication (AASM) and the Sleep Analysis Society (SRS), being held June 1-5, 2024, in Houston, Texas.

“Cognitive functioning is an underappreciated side of sleep issues. Usually overshadowed by clinically defining signs corresponding to EDS, impaired cognition includes important burden to affected person lives. The SHARP examine of solriamfetol confirmed improved cognitive functioning in individuals with impaired cognition related to OSA and EDS,” mentioned Hans Van Dongen, PhD, Professor at Washington State College and presenting writer of the SHARP examine plenary lecture. “As well as, solriamfetol demonstrated enhancements throughout measures of govt operate, reminiscence, and processing velocity.”

Particulars for the shows are as follows:

Title: Solriamfetol on Cognition in Obstructive Sleep Apnea with Extreme Daytime Sleepiness and Impaired Cognition
Lead Writer: Hans Van Dongen, PhD, Professor at Washington State College
Plenary Session: O-09
Plenary Date/Time: Tuesday, June 4 from 9:15-9:30 a.m. Central Time
Poster Session: P-45
Poster Quantity: 390
Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time

Title: Results of Solriamfetol on Cognition on Sufferers with Extreme Daytime Sleepiness Related to Narcolepsy
Lead Writer: Yaroslav Winter, MD, Mainz Complete Epilepsy and Sleep Medication Heart, Division of Neurology, Johannes Gutenberg-College, Mainz, Germany
Plenary Session: O-18
Plenary Date/Time: Tuesday, June 4 from 5-5:15 p.m. Central Time
Poster Session: P-13
Poster Quantity: 266
Poster Date/Time: Monday, June 3 from 11-11:45 a.m. Central Time

Title: Solriamfetol and Upkeep of Wakefulness Outcomes in Sufferers with Narcolepsy and Obstructive Sleep Apnea
Lead Writer: Dr. Michael Thorpy, Director of the Sleep-Wake Problems Heart on the Montefiore Medical Heart and Professor of Neurology at Albert Einstein School of Medication
Poster Session: P-29
Poster Quantity: 324
Poster Date/Time: Tuesday, June 4 from 11-11:45 a.m. Central Time

Title: Actual-world Use of Solriamfetol for Extreme Daytime Sleepiness in Sufferers Reporting Nervousness or Melancholy
Lead Writer: Ulf Kallweit is Assistant Professor of Neurology on the College Witten/Herdecke, Germany.
Poster Session: P-39
Poster Quantity: 200
Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time

Title: SURWEY: Therapy of Extreme Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes
Lead Writer: Samantha Floam, DMD, Axsome Therapeutics
Poster Session: P-29
Poster Quantity: 325
Poster Date/Time: Tuesday, June 4 from 10-10:45 a.m. Central Time

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical firm creating and delivering novel therapies for central nervous system (CNS) circumstances which have restricted remedy choices. By improvement of therapeutic choices with novel mechanisms of motion, we’re remodeling the method to treating CNS circumstances. At Axsome, we’re dedicated to creating merchandise that meaningfully enhance the lives of sufferers and supply new therapeutic choices for physicians. For extra info, please go to the Firm’s web site at The Firm might sometimes disseminate materials, nonpublic info on the corporate web site.

Ahead Trying Statements

Sure issues mentioned on this press launch are “forward-looking statements”. We might, in some circumstances, use phrases corresponding to “predicts,” “believes,” “potential,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “might,” “might,” “would possibly,” “will,” “ought to” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Particularly, the Firm’s statements concerning tendencies and potential future outcomes are examples of such forward-looking statements. The forward-looking statements embrace dangers and uncertainties, together with, however not restricted to, the continued business success of our Sunosi® and Auvelity® merchandise and the success of our efforts to acquire any extra indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and value of our ongoing medical trials and anticipated medical trials for our present product candidates, together with statements concerning the timing of initiation, tempo of enrollment and completion of the trials (together with our potential to completely fund our disclosed medical trials, which assumes no materials modifications to our presently projected revenues or bills), futility analyses and receipt of interim outcomes, which aren’t essentially indicative of the ultimate outcomes of our ongoing medical trials, and/or information readouts, and the quantity or kind of research or nature of outcomes essential to help the submitting of a brand new drug software (“NDA”) for any of our present product candidates; our potential to fund extra medical trials to proceed the development of our product candidates; the timing of and our potential to acquire and preserve U.S. Meals and Drug Administration (“FDA”) or different regulatory authority approval of, or different motion with respect to, our product candidates, together with statements concerning the timing of any NDA submission; whether or not points recognized by FDA within the full response letter might influence the potential approvability of the Firm’s NDA for AXS-07 for the acute remedy of migraine in adults with or with out aura, pursuant to our particular protocol evaluation for the MOMENTUM medical trial; the Firm’s potential to efficiently defend its mental property or receive the required licenses at a price acceptable to the Firm, if in any respect; the profitable implementation of the Firm’s analysis and improvement packages and collaborations; the success of the Firm’s license agreements; the acceptance by the market of the Firm’s merchandise and product candidates, if permitted; the Firm’s anticipated capital necessities, together with the quantity of capital required for the continued commercialization of Sunosi and Auvelity and for the Firm’s business launch of its different product candidates, if permitted, and the potential influence on the Firm’s anticipated money runway; unexpected circumstances or different disruptions to regular enterprise operations arising from or associated to geo-political conflicts or a world pandemic and different elements, together with common financial circumstances and regulatory developments, not throughout the Firm’s management. The elements mentioned herein might trigger precise outcomes and developments to be materially totally different from these expressed in or implied by such statements. The forward-looking statements are made solely as of the date of this press launch and the Firm undertakes no obligation to publicly replace such forward-looking statements to replicate subsequent occasions or circumstance.

Axsome Contacts:

Mark Jacobson
Chief Working Officer
Axsome Therapeutics, Inc.
One World Commerce Heart, 22nd Flooring
New York, NY 10007
Tel: 212-332-3243
E mail:

Darren Opland
Director, Company Communications
Axsome Therapeutics, Inc.
One World Commerce Heart, 22nd Flooring
New York, NY 10007
Tel: 929-837-1065
E mail:

Adblock check (Why?)

Leave a Reply

Your email address will not be published. Required fields are marked *